The stock of Moleculin Biotech Inc (NASDAQ:MBRX) is a huge mover today! The stock decreased 6.24% or $0.38 on September 30, hitting $5.71. About 53,905 shares traded hands or 47.28% up from the average. Moleculin Biotech Inc (NASDAQ:MBRX) has risen 6.00% since September 1, 2016 and is uptrending. It has underperformed by 4.42% the S&P500.
The move comes after 9 months negative chart setup for the $66.62M company. It was reported on Oct, 1 by Barchart.com. We have $4.97 PT which if reached, will make NASDAQ:MBRX worth $8.66M less.
Analysts await Moleculin Biotech Inc (MBRX) to report earnings on November, 21.
According to Zacks Investment Research, “Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.”
More notable recent Moleculin Biotech Inc (NASDAQ:MBRX) news were published by: Marketwired.com which released: “Moleculin Biotech, Inc. Completes Initial Public Offering; MBRX Shares Set to …” on June 01, 2016, also Finance.Yahoo.com with their article: “Moleculin Biotech to Present at OktoberINVESTfest” published on September 23, 2016, Quotes.Wsj.com published: “News Moleculin Biotech Inc.MBRX” on February 11, 2011. More interesting news about Moleculin Biotech Inc (NASDAQ:MBRX) were released by: Marketwatch.com and their article: “Virtual Stock Exchange” published on June 02, 2016 as well as Marketwired.com‘s news article titled: “Moleculin Biotech, Inc. Announces Acquisition of Annamycin Rights” with publication date: October 28, 2015.
MBRX Company Profile
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Firm is focused on the development of anti-cancer drug candidates, many of which are based on license agreements. The Company’s lead drug candidate is liposomal Annamycin (Annamycin). The Firm has two other drug development projects in progress, one involving a portfolio of small molecules, known as the WP1066 Portfolio, and the other is WP1122 Portfolio. WP1066 Portfolio is focused on the modulation of key regulatory transcription factors involved in the progression of cancer. WP1122 Portfolio is a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (a form of brain tumor).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.